



Iveta Dzivite-Krisane

**MOLECULAR MECHANISMS,
IMMUNOGENETIC CHARACTERISTICS,
CLINICAL AND THERAPEUTICAL
CONSEQUENCES OF THE
21-HYDROXYLASE DEFICIENCY IN THE
LATVIAN CHILDREN**

(Speciality – paediatrics)

SUMMARY OF THE DOCTORAL DISSERTATION

Riga, 2010

Prk - 3770

139340

Riga Stradins University

Iveta Dzivite-Krisane

MOLECULAR MECHANISMS,
IMMUNOGENETIC CHARACTERISTICS,
CLINICAL AND THERAPEUTICAL
CONSEQUENCES OF THE
21-HYDROXYLASE DEFICIENCY IN THE
LATVIAN CHILDREN

(Speciality – paediatrics)

SUMMARY OF THE DOCTORAL DISSERTATION

Riga, 2010

0221007619

The Doctorate work was prepared:

- Clinical part of the Doctoral program performed at the Children Clinical University Hospital in Riga;
- At the Riga Stradins University;
- Experimental part performed at the Children Endocrinology Centre and at the Endocrinology Scientific Laboratory of Karolinska Institute in Sweden, Stockholm.

Scientific Supervisor:

Dr.habil.med., professor Dace Gardovska

Scientific Consultant:

Dr.biol., professor Edvins Miklasevics

Official reviewers:

Dr.habil.med., professor Aivars Lejnicks (RSU)

Dr.habil.med., professor Valdis Pirags (LU)

Dr.habil.med., professor Danute Lasiene (Kaunas University of Medicine)

Presentation of the Doctorate paper will take place on 15th of March, 2011, at 15.00 during the Riga Stradins University Internal Medicine Doctorate Board meeting in the RSU Hipocrates auditorium, Riga, Dzirciema str. 16.



The Doctorate thesis can be acquainted at the Riga Stradins University Library.

Secretary of the Doctorate Board:
Professor, Dr.habil.med. Maija Eglite

Abbreviations used in the paper

Numbers

11beta-HSD - 11-beta hydroxysteroid-dehydrogenase

17-HSD - 17- hydroxysteroid-dehydrogenase

17-OH-P - 17-hydroxy-progesterone

21-H - 21-hydroxylase

21-HD - 21-hydroxylase deficiency

3-beta-HSD - 3- hydroxysteroid-dehydrogenase

A

ACTH - adrenocorticotropic hormone

B

BKUS – Children Clinical University Hospital

C

cAMP - cyclic adenosine-monophosphate

CRH - corticotrophin-releasing hormone

CAH – congenital adrenal hyperplasia

D

ddNTF - 2,3-di-desoxynucleoside triphosphate

DHEA - dehydro-epi-androsterone

DHEA-S - dehydro-epi-androsterone sulphate

DNA – desoxynucleic acid

DOC – desoxicorticosterone

E

ECG - electrocardiogram

ESPE - European Society of Pediatric Endocrinology

G

GC - glucocorticoids

GnRH - gonadotropin-releasing hormone

I

IGF - insulin-like growth factor

P

P - progesterone

PCR - polymerase chain reaction

PRA - plasma renin activity

S

StAR - acute regulating protein of steroidogenesis

SL – salt lost form of the CAH

T

TNF - tumour necrosis factor

V

SV - simple virilising form of the CAH

1. Introduction

Congenital adrenal hyperplasia (CAH) or the hereditary adrenogenital syndrome (AGS) is one of the most common congenital metabolic defects based on the deficiency of one or several steroid biosynthesis enzymes that is autosomal-recessive and monogenically determined. Deficiency of each of these enzymes results in particular, typical metabolic and clinical signs in CAH patients, but the common characteristic symptom in such a patient is the development of glucocorticoid insufficiency with the consequential compensatory, adrenocorticotrophic hormone (ACTH)-hyperstimulated hyperplasia of the adrenal cortex.

1.1. Topicality of the research paper

Clinicians and scientists engaged in the medical research do pay more and more attention to the hormonal processes in critically ill patients trying to find out the factors the changes of which determine the disease outcome in such situations. Without doubt, adrenal cortex hormones are the one of most essential among these factors, therefore, individuals with hereditary secretional deficiency of these hormones promote special clinical and theoretical interest, since controlled adrenal cortex insufficiency may develop into uncontrolled in stress situations resulting in a life threatening acute adrenal insufficiency crisis symptoms. Since the incidence of milder forms of CAH in definite populations may be up to 1:100 [1, 5-7], the topicality of this problem should not be underestimated.

In Latvia, no CAH study in both the clinical and scientific direction has been performed up to now.

HLA III class genes studies in a specific population are urgent also due to the fact that the disease markers in different ethnic groups are not similar.

The Doctorate paper could give a development of a new CAH diagnostics option and a choice for a correct treatment strategy, including the prenatal diagnostics and treatment.

The main targets for a timely CAH diagnostics and treatment are:

- Reduction of neonatal mortality from undiagnosed acute adrenal insufficiency crisis in the case of CAH salt loss form,
- Establishment of a correct gender of the newborn in the case of IV - V level of virilisation (according to *Prader*), and avoidance of further medical, psychological and social problems caused by the gender change (according to the genetic gender),
- Reduction of the infertility problem.

The Doctorate paper is the first CAH study in children in Latvia.

1.2. Statement of the problem

Since CAH is a hereditary metabolic defect that may lead to the mortality of the newborn or the infant in the case of the salt loss form the direct cause of which is an acute adrenal insufficiency, the prenatal screening is strictly considered as justified for the establishment of this pathology and induction of the prenatal therapy. At present, this screening diagnostics is based mainly on the molecular genetic examinations, and it is an extensively introduced clinical routine method in many countries. According to the clinical experience up to now, steroid 21-hydroxylase deficiency may be caused

by many mutations of its gene (*CYP21* gene), besides, some of them are predominant in some populations [17,19,20,24,28,84].

Several unsolved problems exist clarification of which could improve the diagnostics of 21-hydroxylase deficiency and establishment of the disease risk and prognostic factors:

- Evaluation of the disease epidemiologic parameters dynamics to define precisely the role of CAH in the structure of pediatric chronic pathology, research of the disease initial versions development,
- Establishment of HLA III class genes and specific genes alleles mutations and relationship to CAH in order to identify immunogenetic markers of the disease and its clinical forms,
- Establishment of the risk factors (immunogenetic, clinical) for the disease in total and for its clinical forms,
- Establishment of predictive signs in patients with the simple virilizing form in order to develop timely algorithms for diagnostics of this form.

1.3. Purpose of the paper

Purpose of the Doctorate paper is to investigate molecular mechanisms, immunogenetic characteristics of the 21-hydroxylase deficiency and their clinical and therapeutic consequences in children in Latvia.

1.4. Work tasks

- To establish the potential relationship between the most common HLA haplotypes in Latvia related to CAH and the clinical forms of CAH, differences of CAH development HLA haplotypes in Latvia from the ones in Europe,
- To establish *CYP21* gene mutations predominant in Latvia,
- To establish differences of the predominant *CYP21* gene mutation range from the ones found in the European countries,
- Dynamic analyze of the course of CAH in included in the study children during the 5-years follow-up period.

1.5. Ideas posed for the presentation

- Predominant range of *CYP21* gene mutations in Latvia is similar to the one found in European countries,
- CAH incidence in Latvia does not significantly differ from the one found in the Baltic and Nordic states region,
- CAH screening of newborns is an objective need to contribute to the reduction of infant mortality from timely undiagnosed acute adrenal insufficiency, to establish the correct gender of the newborn in the case of the girl's virilization, to reduce infertility problems in CAH patients during the fertile age.

1.6. Hypotheses

- The range of the predominant *CYP21* gene mutations in CAH patients in Latvia is similar to the one found in European countries,

- HLA III class haplotypes in CAH patients in Latvia do not differ from the ones found in European countries.

2. Novelty of the results

1. For the first time, CAH epidemiologic data in Latvia have been collected and evaluated in progress. Since the data collection and analyses methodology used in the work has been chosen according to international standards, results obtained are comparable to results from another countries of the world. That, on its turn, has allowed to establish that the CAH morbidity in Latvia is lower compared to the one found in Northern European states.
2. CAH development risk factors in Latvia have been found not to differ significantly from those in the Northern European region, and they are related to the HLA-B14;DR1 haplotype and HLA-A3;Bw47;DR7 haplotype.
3. It has been established that Latvian patients with the CAH salt loss form predominantly have large deletions and conversions of *CYP21* gene, also point mutations (A / C to G) in the introne 2.
4. It has been established that Latvian patients with the CAH simple virilizing form predominantly have Ile-172 to Asn mutations.
5. It has been established that Latvian patients with the CAH classic form predominantly have Val281Leu and Pro30Leu mutations.

3. Structure and scope of the Doctorate paper

The Doctorate paper is written in Latvian. It consists of the Title page and 10 sections. The essence of the paper is given in 4 sections, but the rest 6 sections are devoted to the introduction, conclusions, novelty of results, synopsis of the work, literature references, and annexes, respectively. The paper is no 136 pages in typewriting. It has been illustrated by 22 tables and 52 figures. The paper has 27 annexes.

4. Materials and methods

4.1. Characteristics and selection of patients

Data on 53 patients with 21-hydroxylase deficiency used in the study have been aggregated in the Children Clinical University Hospital's (BKUS) Children and Adolescent Endocrinology Centre Congenital Adrenal Hyperplasia Patient Register. Register of the above mentioned disease patients thanks to the enthusiasm of physicians was started on 1989 based on the children endocrinology department.

Patients age was 0 to 18 years.

In the study, prospective and retrospective data analyses during the period from 1989 to 1992 was undertaken. In the retrospective study, all patients with CAH classic form were involved.

Patients were selected according to the IDC-10 diagnosis code E25.0.

Primary data source: BKUS endocrinology centre patients' hospital disease histories and out-patient records.

Secondary source: excerpts from out-patient records by family physicians.

53 disease cases of 21-hydroxylase deficiency (salt loss and simple virilizing forms) in Latvian children have been evaluated.

For each patient, a questionnaire “Initial information on CAH patient” and “Current information on CAH patient” was filled out and data were analysed.

Blood samples for immunogenetic and molecular genetic evaluations were taken during the period from 2000 to 2004 from all 53 patients following written consent from the parent or legal guardian of the child (consent and information forms on the study “Consent to the molecular genetic study” and “Information for the study subject’s parents”).

Prior to the involvement in the study, in all patients CAH diagnosis was confirmed based on diagnostic criteria developed by the ESPE (*European Society of Pediatric Endocrinology*).

Two control groups were arranged: for immunogenetic control: 20 healthy, non-relative children; for molecular genetic control: 10 healthy, non-relative children.

Venous blood samples were collected in cases not associated with an autoimmune, infectious or endocrine pathology. Control group children were matched to patients by the age and gender.

During the recent 5 years (year 2009 included) a follow-up of all 53 studied children with CAH was carried out and a course of their disease was dynamically analyzed using following criterias:

- clinical data – actual height, final height, age of puberty onset and age of menarche,
- biochemical findings – diagnostic levels of 17 α OHPg, Na and K in blood and oscillations of the level of 17 α OHPg during follow-up period,
- schedule of therapy,
- complications.

Children with CAH were under the care of BKUS Children and Adolescent Endocrinology Centre, therefore, data obtained in this research allow to a certain extent to judge on this problem in Latvia both in general and in some of its regions, as well as to compare the incidence of CAH in our country with the data in neighbouring countries and world-wide.


Central Statistics Administration of the Republic of Latvia data on the annual birthrate and the number of children in Latvia have been used to calculate the epidemiologic parameters.

4.2. Study subjects

Data and clinical material from 53 paediatric patients with CAH were taken and analysed for this research. 30 patients were boys, but 23: girls; 4 of boys included in the study genetically were girls with CAH-related severe virilisation. In 29 patients, CAH salt loss clinical form was diagnosed, but in 24: simple virilizing form.

Development of external genitals was evaluated according to *Prader* virilisation scale (see figure 1).

Prader virilization scale [235].



Prader 0: Normal female external genitalis.

Prader I: Female external genitalis with enlarged clitoris: clitoromegalia.

Prader II: Clitoromegalia with partial merging of labia that form a funneled urogenital sinus; vagina and urethra opens in this funnelled formation.

Prader III: Clitoromegalia reaches the size of phallus; complete merging of labia that form an urogenital sinus where vagina and urethra opens; the urogenital sinus has one external opening.

Prader IV: External genitalis are composed of phallus and completely merged labia making a scrotum-like formation; vagina and urethra opens in a common opening at the base of phallus.

Prader V: External genitalis look like normal male external genitalis; vagina and urethra opens in a common opening at the end of phallus.

Growth of patients was assessed according to charts of standard deviations (SDS).

Puberty was assessed according to Tanner criterias for puberty stages regarding the onset of puberty at testis volume 4 ml for boys, and breast enlargement for girls [237].

Level of $17\alpha\text{OHPg}$ in blood was analyzed according to criterias of appropriate laboratory reference.

Genetic gender of the patient was established by a routine karyotype analysis at the State Genetics Centre.

4.3. Inclusion criteria

The study involved patients with clinically confirmed classic CAH form according to diagnostic criteria elaborated by ESPE [215] according to the IDC-10 diagnosis code E25.0.

Control group included BKUS patients with acute respiratory disease diagnosis without clinical and laboratory signs of any other health disorder.

4.4. Exclusion criteria

Patients who parents did not agree participating in this research study (theoretically). We did not receive any disagreement.

4.5. Diagnostics and classification

CAH is diagnosed by clinical, hormonal and molecular genetic criteria based on CAH diagnostic standards elaborated by ESPE and *Lawson Wilkins Endocrine Society* in collaboration in 2002 [3,4,31,209,210,213,215,218].

4.6. Applied methods

4.6.1. Primers used for CYP21/CYP21P molecular analysis

For *CYP21* / *CYP21P* molecular analysis, primers manufactured by *Metabion International AG* (Germany) were used.

4.6.2. DNA extraction from blood

For extraction of chromosomal DNA (chrDNA), 2 to 3 ml of blood are used. Blood is collected in vacutainer tubes containing EDTA or citrate buffer, thus preventing blood clotting.

Blood is stored at - 20°C - 70°C. Repeated unfreezing of blood is not recommended.

chrDNA is extracted from leucocytes with the help of commercial *Qiagen* kit for DNA extraction from blood (*QIAamp® DNA Blood Mini Kit*) according to the technology approved by the manufacturer.

4.6.3. Detection of CYP21 gene mutations with PCR

Polymerase chain reaction (*PCR*) is being extensively used in various biology and medicine fields, diagnostics, reproduction of DNA fragments, mutagenesis and sequencing.

The method is based on the DNA amplification performed by a thermostable polymerase (*Taq* polymerase). *PCR* is based on 20 to 40 times repeated DNA synthesis cycles. Each cycle of the synthesis consists of three stages of reaction: DNA denaturation, primer hybridization and DNA synthesis.

Material for testing 10 µL was suspended in 200 µL of normal saline, and 2 µL were used as a matrix for the amplification with specific primers (see Table 1). For the preparation of *PCR* amplification reaction of one sample, 10 mM dNTP mixture – 0.1 mM was used, corresponding primers 200 mM, MgCl₂ – 1.5 mM, *Taq* polymerase - 1 U, distilled water added up to 12.5 ml.

PCR amplification product was rectified with kits according to the manufacturer's instructions. *PCR* amplification product was divided in 2% agarose gel for the use for DNA sequencing, and it was visualized with ethidium bromide.

4.6.4. DNA sequencing

For DNA sequencing, *Big Dye* kit (*Biosystems, UK*) was used. Reaction was carried out according to the manufacturer's instructions. Reaction was analysed with the help of the same primers like in the *PCR* reaction.

4.6.5. Haplotyping of HLA gene

1. HLA A,B,C genes amplification

Genome DNA have been obtained from patients' and control group's peripheral blood leucocytes. HLA gene 2nd polymorphous exon also underwent the amplification. Amplification *PCR* took place in the programmed terminal cycler (*Perkin Elmer, Cetus, Connecticut, USA*). HLA B amplification was done in 30 cycles: denaturation at the temperature 95° C for 1 minute, hibridization at the temperature 55° C for 1 minute, synthesis at the temperature 72° C for 2 minutes. 35 cycles were used for HLA A amplification: denaturation at the temperature 94° C for 1 minute, hibridization at the temperature 62° C for 1 minute, and synthesis at the temperature 72° C for 2 minutes. For the amplification of the second HLA exon, primers from *Erlich, Bugawan* were used.

2. HLA B gene typing

HLA B gene typing was performed with a low resolution polymerase chain reaction (*low resolution PCR-SSP*) using sequence-specific primers according to the methods specified by the manufacturer (*BA Gene; BAG Lich, Germany*). The main types of HLA B alleles have been identified.

4.7. Statistical analysis of the obtained results

SPSS program was used for the data treatment, T-test for the data comparison, but for the data analysis: descriptive and conclusive statistical methods.

According to the proposed tasks and kind of data, parametrical and non-parametrical statistical methods were used.

For the statistical treatment of the obtained results, the following methods were used:

- Central trend values with the calculation of the arithmetical mean,
- Dispersion for the data characterised by the standard deviation,
- Chi - square test (c2 test),
- CI analysis: (*Wilson* method) for the calculation of one sample data interval,
- *Newcombe* method: proportions and their differences,
- linear regression method.

As statistically reliable, significance level $p < 0.05$ was accepted.

For the evaluation of hypotheses, parameters differences were evaluated with the confidence 95% that corresponds to the significance level $p=0.05$.


5. Results

5.1. Epidemiological research finding

The number of new CAH patients tends to increase during the last years. Namely, if the median number of new CAH patients is 1.6 per year during the first 5 years included in the research (from 1984 to 1988), then during the next 5 years (1989 - 1993): 2 per year, from 1994 till 1998: 2.8 per year, but during the last years of the research (i.e. 1999 - 2008) 5 new CAH patients per year on average have been diagnosed (see Figure 2).

Figure 2


CAH morbidity in Latvia (1984 - 2008)



Almost one third of CAH patients included in the study live in Riga. Since the absolute number of patients is listed here, and the relation of the number of patients to the number of inhabitants is not considered, the result could be explained by the fact that almost half of the Latvian population live in Riga.

On the other turn, the number of CAH patients living in the Eastern part of Latvia (Vidzeme and Latgale) significantly exceed the number living in the Southern (Zemgale) and Western part (Kurzeme) of Latvia.

Number of CAH patients in the regions of Latvia



It can be seen that, out of the Latvian administrative units, more CAH patients live in the large towns: Riga, Daugavpils, Liepaja, Jurmala, Valmiera and Jelgava, but less in the southern and western regions of Latvia (see Figure 3).

The latest trend of increased number of new CAH patients can be attributed also to the new patients with CAH classic type salt loss form, i.e., if the number of these patients at the beginning of the monitoring period was on average 1 per year, then during the last years it is about 3 per year.

5.2. Evaluation of the clinical material

5.2.1. Patient population structure

The patient population structure shows that patient groups by the genetic gender are almost the same by numbers, and that patients with the salt loss form are more than patients with the simple virilizing form.

Figure 4 shows one of the main CAH problems: severe virilization of a girl when the gender is defined incorrectly at birth, i.e., 4 of boys included in the research turned out to be severely virilized girls with incorrectly defined gender at birth.

Figure 4

General characteristics of CAH patients





Figure 5

General characteristics of CAH patients with the salt loss form



Among CAH patients with the salt loss form included in the research, most are girls. Obtained results, as can be seen in the Figure 5, show that a severe virilization is not the leading symptom of this form.

On the other turn, in the group of patients with CAH simple virilizing form, boys prevail (which is difficult to explain, since the virilization in boys can be diagnosed only in very severe cases).

Four girls of genetic gender in whom the gender was diagnosed incorrectly at birth have CAH simple virilizing form.

Figure 6 shows that the virilization is the leading symptom of CAH simple virilizing form.

Virilization stages according to *Prader* III - V causes problems with a correct establishment of girl's gender at the obstetrician department. Commonly this mistakes is made, because external genitals are not palpated and the absence of testes is not established, and the phenotypical gender, boy, is established that does not correspond to the genetic gender, girl.


5.2.2. Patient characteristics by birth parameters related to the age at CAH diagnosis

CAH salt loss form in 20% of patients is diagnosed during the first 2 weeks of life, in about 40% of patients within 1 month, in about more 30% in the 2nd month, but when the age of 3 months is reached, the diagnosis has been established in all patients of this group (see Figure 7).

However, previously the CAH simple virilizing form in patients has been diagnosed within first 6 months and first 2 years (see Figure 8). It has been established by a noticed virilization. Another rise in a more active diagnostics is about the beginning of puberty. This is, however, established by a premature puberty onset in boys or delay in girls.

Figure 6

Characteristics of patients with CAH simple virilizing form



Age of CAH diagnostics in patients with the salt loss form




Figure 8

Age of CAH diagnostics in patients with the simple virilizing form





Figure 9

The level of virilization in CAH patients depending on the disease form




5.2.3. Patients characteristics by the virilization stage

Out of all 53 CAH patients involved in the study, virilization was observed in 24, i.e., 45.3%. In one third CAH patients involved in the study a severe virilization (Stage III according to *Prader* or higher) was diagnosed. At the same time in more than a half of patients no virilization was observed. This mainly applies to boys in whom the virilization can be noticed only in very severe cases. Besides, as can be seen in the Figure 9, disproportionally low seems the incidence of a mild virilization. It is possible that a mild virilization in these patients was considered as normal. So the biggest part of CAH patients without virilization are boys and virilization underdiagnostics.

In patients with CAH simple virilization form have all stages of virilization equally, but in patients with the salt loss form mild stage of virilization is less common, but more severe stages of virilization are more common.

In the case of CAH salt loss form, the severe virilization diagnosed should be attributed to the total deficiency of 21-hydroxylase that results in a high hyperandrogenemia already during the intrauterine period, and determines the development of gender differentiation disorders that may require surgery to be eliminated.



Totally, 35 genital plastic surgeries have been performed. In 11 patients genitals two-stage surgical corrections have been performed. In 4 cases, phenotypic gender does not correspond to the genetic one.

Most commonly, clitoris correction was required due to its enlargement.

Vaginal plastic surgery was mostly needed to remove the urogenital sinus.

In 3 cases, complex measures to change the gender were performed.

Genetic gender change (severe medical, legal and psychosocial problem) was performed in 3 cases, i.e. in 10% of the total number of surgeries (95% CI 3.5 - 25.6%).

Vaginal plastic surgery in CAH female patients due to severe virilization was performed within the first two years of life, clitoris correction up to the age of 4, but the gender change was performed at the age of 8 to 10 years (see Figure 10 and Figure 11).

Figure 10

Types of surgical plastics in virilized CAH girls





Figure 11

Age at the surgical plastics




5.3. Molecular genetic analysis of the clinical material

5.3.1. CYP21A2 gene amplification with PCR method

During the work, chromosomal DNA was extracted from the patients' blood, then *CYP21A2* gene amplification with *PCR* method was performed, *CYP21A2* gene sequenced, and sequencing results were analysed.

Figure 12 shows an example of *CYP21P/CYP21* gene analysis performed in the study. A,B - *CYP21P/CYP21* molecule analysis following secondary *PCR* product (132-bp) – amplification with the help of *SacI* restriction enzyme. C,D - “size-different” *PCR* products analysis by the amplification with mixed primers B1/2HP/IN3R. Primers B1/IN3R and 2HP/IN3R in a secondary *PCR* amplification activate 307- and 281-bp fragments. Primary *PCR* amplification with primers BF1/21BR is analyzed in A and B. Primary *PCR* amplification with mixed primers BF1/AF1/21BR is analyzed in C and D. Column “mk” - 100-bp molecular marker.

CYP 21P/CYP21 gene analysis following secondary PCR product (with the same type of primers)



5.3.2. CYP21A2 gene sequencing and results obtained

For detection of mutations that can't be detected with the *PCR* methodology, sequencing was used.

All 10 gene *CYP21A2* exons were sequenced, since it is not long (only 3336bp). Results in exons 1, 2, 3 were convincing, since it was possible to sequence 847bp (P1+P48) *PCR* fragment precisely, however, the quality of sequences obtained in sequencing of 2508bp (P55+P4) *PCR* fragments is unsatisfying unfortunately.

For the development of a complete gene *CYP21A2* sequencing, it would be necessary to change the *PCR* strategy for *CYP21A2* gene exons 4-10 amplification, taking into consideration the existence of *CYP21A2P* pseudogene.

5.3.3. HLA locus finding in CAH patients

The research finding shows the relationship between HLA locuses A1, Bn47 and B60 with the development of CAH salt loss form, but HLA locuses B14 and Bw51 are related to the development of CAH simple virilizing form. HLA locus A3 is related to the development of both CAH salt loss and simple virilizing form (see Figure 13 and Figure 14).

Figure 13

Relationship of HLA locus finding in CAH patients with SL and SV forms





Figure 14

HLA locus relationship to the development of a definite disease form




According to the research data, HLA locuses Bn47, A1 and B60 are related to the development of CAH salt loss form, but HLA locuses B14 and Bw51: to the development of the simple virilizing form.

5.3.4. CYP21 gene mutations finding in CAH patients

Figure 15

Summary of CYP21 gene mutations finding in CAH patients.



The most common found CYP21 gene mutations in CAH patients are 12G/12G mutations intron 2, also - Ile172Asn and 8-bp deletions in exon 3 (see figure 15).

CYP21 gene 12G/12G mutations intron 2 and other 12G depending mutations (12G/del, 12G/E38bp, 12G/R356W) involving with CAH salt loss form development in boys and also in girls.

CYP21 gene Ile172Asn depending mutations (I172N/del, I172N/E38bp, I172N/12G I172N/R356W) involving with CAH simple virilizing form development, more in boys than girls.

CYP21 gene Val281Leu and Pro30Leu mutations involving with CAH simple virilizing form development.

In CAH patients 12G/V281L mutation was found in girl, but del/V281L and P30L mutations – in boys.

CYP21 gene del/I172N-F306+t mutation involving in virilization of CAH salt loss form.

12G/del, 12G12G and 12G/R356W mutations involving in virilization of CAH salt loss form and simple virilizing form also. CYP21 gene I172N/del, I172N/R356W and I172N/E38bp mutations involving with CAH simple virilizing form development.

5.4. Dynamic analyze of the course of CAH included in the study children during the 5-years follow-up period

During the recent 5 years (year 2009 included) a follow-up of all 53 studied children with CAH was carried out. Number of outpatient visits during the first year of life was 3 ± 1 (recommended – 4), but after the age of 1 year – 2 ± 1 (recommended – 3).

During the follow-up period 14 patients (8 patients with salt wasting form and 6 patients with simple virilizing form) born in years 1984 – 1991 have reached the age of 18 years. The rest 37 patients (19 patients with salt wasting form and 18 patients with simple virilizing form) are growing up. 2 patients with salt wasting form have had exitus letalis.

Patients reached the age of 18 years during follow-up period have grown-up to their final height as follows:

- girls: -1.9 ± 0.4 SDS (among them, girls with salt wasting form have grown-up to -1.7 ± 0.4 SDS, but girls with simple virilizing form have grown-up to -2.0 ± 0.4),
- boys: -1.7 ± 0.3 SDS (among them, boys with salt wasting form have grown-up to -1.5 ± 0.2 SDS, but boys with simple virilizing form have grown-up to -1.9 ± 0.2 SDS).

Analyze of gene mutations in the group of grown-up 14 patients has revealed that existance of salt wasting form is connected with 12G/12G and 8-bp deletion in exon 3 mutations, but existance of simple virilizing form is connected with Pro30Leu, Val281Leu, Ile172Asn mutations.

Analyze of growth pattern in the group of growing-up 39 patients has revealed growth dependency on age as follows:

- from birth to 6 months: -0.5 ± 0.3 SDS
- 6 months to 1 year: 0.1 ± 0.2 SDS
- 1 year to 2 years: 0.7 ± 0.4 SDS
- 2 years to 5 years: 0.9 ± 0.3 SDS
- 5 years to 10 years: 0.6 ± 0.4 SDS
- 10 years to 15 years: boys – -1.1 ± 0.5 SDS, girls – -0.9 ± 0.4 SDS.

Onset of puberty for girls (n = 16) has been at age of 10.1 ± 0.6 years, menarche (n = 12) at age of 13.4 ± 0.4 years, while onset of puberty for boys (n = 20) has been at age of 9.2 ± 0.5 years.

Levels of electrolytes in the blood at the time of CAH diagnostics were as follows:

- Sodium 125 – 134 mmol/l found in 35 patients (66 %),
- Sodium below 125 mmol/l found in 13 patients (24.5%),
- Potassium 5 – 7 mmol/l found in 21 patients (39.6%),
- Potassium above 7 mmol/l found in 29 patients (54.7%).

29 patients have documented symptoms of acute suprarenal insufficiency as clinical signs of their salt wasting form of the CAH.

Level of $17\alpha\text{OHPg}$ in the blood as basic criteria for CAH diagnostics is used in 45 patients (85% of all patients). In 8 patients at the time of CAH diagnostics is estimated the level of 17-ketosteroids in urine. Diagnostic level of $17\alpha\text{OHPg}$ was found between 15.9 ng/ml to 200.7 ng/ml, in average – 40.08 ng/ml (n = 45, $p < 0.05$).

Oscillations of the level of $17\alpha\text{OHPg}$ during the follow-up period of patients was found between 0.3 ng/ml to 121.4 ng/ml, in average – 24.716 ng/ml (n = 1060, $p < 0.05$). In the group of patients at age of 10 – 15 years the mean value of $17\alpha\text{OHPg}$ was 45.76 ng/ml (n = 486, $p < 0.05$). No statistically safe difference was revealed between oscillations of $17\alpha\text{OHPg}$ in salt wasting and simple virilizing forms.

Analyze of the schedule of therapy revealed following:

- Regardless of the form of CAH all patients have received treatment with glucocorticosteroids:
 - o 16 patients (30.2%) regularly and 12 patients periodically (independently on CAH form) have received Prednisolone in doses as follows:
 - up to age of 1 year – 3.4 ± 1.2 mg/m²,
 - from 1 year to 10 years age – 6.2 ± 1.3 mg/m²,
 - from 10 to 18 years age – 7.9 ± 1.2 mg/m².
 - o 25 patients (47.2%) regularly and 12 patients periodically have received Hydrocortisonum in doses as follows:
 - in case of salt wasting form: up to age of 6 months – 23.4 ± 1.9 mg/m², from 6 months to 1 year age – 19.2 ± 2.1 mg/m², from 1 year to 10 years age – 17.4 ± 1.5 mg/m², from 10 to 18 years age – 20.5 ± 1.4 mg/m²,
 - in case of simple virilizing form: up to age of 1 year – 18.4 ± 2.3 mg/m², from 1 year to 10 years age – 13.8 ± 1.3 mg/m², from 10 to 18 years age – 24.8 ± 1.3 mg/m².
- 29 patients with salt wasting form have received mineralocorticoids - 9α fludrocortisonum as a single daily dose according to their age as follows:
 - o up to age of 3 months – 150 $\mu\text{g}/\text{m}^2$, from 3 months to 1 year age – 100 $\mu\text{g}/\text{m}^2$, from 1 year to 2 years age – 50 to 100 $\mu\text{g}/\text{m}^2$, after age of 2 years – 50 $\mu\text{g}/\text{m}^2$.
- All 29 suffering from salt wasting form of CAH additionally have received NaCl 1 – 2 g/day up to age of 1 year.

Severe complications of CAH among patients included in the study have documented 15 times in 12 patients (22.6%), all suffering from salt wasting form and having at least one of the following mutations – I2G/I2G, I2G/R356W, I2G/del, Q318X/R356W, R356W/R356W. There were 2 lethal cases (1.06%) among patients studied, both in boys, one case – pneumonia at age of 8 months, another case – meningococemia at age of 2 years. In 3 patients observed repeated acute adrenal crises. All cases (100%) of acute suprarenal insufficiency developed in patients during acute intercurrent illnesses, mainly (in 10 cases) during gastrointestinal infections. Hypoglycemia observed in 9 cases (7.8%) at age from 8 months to 3 years. Salt wasting crisis with hyponatremia have been documented in group of patients at age 1.8 to 4.6 years.


6. Discussion

Epidemiologic data

When congenital adrenal hyperplasia research was started, at first it seemed important to evaluate the incidence of this congenital metabolic disease in Latvia and to compare it with similar research data in neighboring countries and world-wide (see Figure 16). Such comparison of data shows that the CAH morbidity in Latvia is on average by 5000 lower than in Northern European countries. It means that there is one CAH patient per 17 795 newborns in Latvia, while in Sweden this value is 1:12578, but world-wide: 1:14000. However, when overall study data are analyzed, it can be concluded that there is an underdiagnostics of CAH in Latvia, and the number of CAH patients in our country could be greater.

Figure 16

CAH incidence world-wide



Although the number of patients involved in our research is not high, the data collected give some insight into the incidence of CAH in our country, and may serve as a basis for discussion on the need for CAH neonatal screening in Latvia as well.

The research revealed that one third of CAH patients involved in the study live in Riga. Since the absolute number of patients was counted, not the proportion of patients against the population, such result can be explained by the fact that almost one half of the Latvian population live in Riga. However, the number of CAH patients who live in the Eastern part of Latvia (Vidzeme and Latgale) significantly exceeds the number of patients living in the Southern (Zemgale) and Western part (Kurzeme).

Collected data show that CAH patients outside Riga are located mainly in the large towns: Daugavpils, Liepaja, Jurmala, Valmiera and Jelgava, less in Southern and Western regions of Latvia. Part of CAH patients in rural areas remain undiagnosed, since, unless it is a salt loss form, this disease is not life-threatening in an everyday life. At the same time, with severe stress, infections, injuries or similar situations CAH patient may develop an acute adrenal insufficiency or the adrenal crisis that is life-threatening. In particular, this applies to pediatric patients with this pathology, and it is understandable why clinical pediatricians world-wide pay more attention to the CAH problem. Namely, the question that is being asked and discussed within the pediatric endocrinologists' society is: "How much lives can be saved by prenatal CAH diagnostics or neonatal CAH screening?". Up to now world-wide, more than 6.5 millions of newborns have undergone the CAH screening. In many countries, this has become a clinical routine, and this research is a step to promote such a need in Latvia as well.

Evaluation of data collected during the study on CAH morbidity in Latvia shows that a trend to an increased number of new CAH patients can be observed during the last years. Namely, if the number of new CAH patients within the first 5 years included in the research (from 1984 to 1988) is 1.6 per year on average, within the next 5 years (1989 - 1993): 2 per year, within the period from 1994 to 1998: 2.8 per year, then during the last 4 years of the research (1999 - 2002) 5 new CAH patients were diagnosed per year on average. The mentioned above is equally applicable both to the CAH salt loss and the simple virilizing form. Knowing that the incidence of the simple virilizing form is higher compared to the salt loss form, data collected in the study probably do not show the real number of patients with CAH simple virilizing form in Latvia (which should be significantly higher compared to the number of patients with the salt loss form). The Reason could be the relatively mild clinical course of this form that, to the contrary to the salt loss form, does not force to seek medical advice.

Clinical data

CAH patients group included in the study is composed of 30 boys and 23 girls; 4 of these boys genetically are girls with a severe virilization; therefore, 26 boys and 27 girls have been evaluated during this research which shows that no gender difference is being observed in the development of CAH: this observation conforms to the literature data.

CAH salt loss form is found in 55% of cases, but the simple virilizing form: in 45% of cases. The incidence of both CAH forms has a gender difference: salt loss form has been diagnosed in 40% of boys and 74% of girls, but the simple virilizing form in 60% of boys and 26% girls. These data could probably show the

acknowledged clinical problem, i.e. CAH underdiagnostics in boys, since the virilization signs in newborns / infant boys usually are unnoticeable.

When these study data are evaluated, it becomes clear that there is a need for additional educational information for parents, children and also doctors on CAH simple virilizing form and problems caused by it, since there are certainly more girls suffering in Latvia compared to the number revealed by the study.

CAH salt loss form in 20% of patients was diagnosed during the first 2 weeks of life, in about 40% of patients in 1 month, in another 30% in 2 months, but when the age reaches 3 months, the diagnose has been established in every patient of this group.

Patients with the CAH simple virilizing form were diagnosed earlier, within first 6 months and first 2 years of life. This is due to the noticed virilization. The other rise in a more active diagnostics has been around the onset of puberty. That, on its turn, is caused by a premature puberty onset in boys or delay in girls.

The mean age for diagnostics of the simple virilizing form is 39 weeks (9.7 months), but for the salt loss form: 1.4 months. In general, the mean age for CAH diagnostics in Latvia is 5.2 months, while in Europe such diagnostics usually takes place by the age of 3 months.

Regarding clinical manifestation of virilization, a certain polarisation of its clinical signs exist. From one side, most of evaluated patients (i.e., 54.7% of all CAH patients or separately: 51.7% with the salt loss form and 58.3% with the simple virilizing form) did not have any virilization signs at the time of CAH diagnostics. Virilization signs probably were not looked for sufficiently enough. From the other side, severe (degree III to V) virilization has been found in 40% of patients with the salt loss form and 25% of patients with the simple virilizing form. These data also could reveal the clinical practice that sometimes exists, i.e., less severe virilization signs remain unnoticed.

Like regarding the incidence of CAH forms, also regarding the incidence of virilization, there are big differences between genders in the study results. Namely, in 86% of boys and 13% of girls no virilization was observed at the time CAH was diagnosed, but degree III to V virilization in girls has been found in 77% of cases, while in boys it has not been found at all.

Since the virilization in girls is one of the leading CAH symptoms, the need to perform genitoplastic surgery was analysed during the study. It turned out that 35 genitoplastic surgeries were performed in total in female patients with CAH included in the study. Most commonly, i.e., in 23 cases, there was a need to perform a clitoris correction due to the enlargement. Vaginal plastics was performed in 9 cases, mainly for removing of urogenital sinus. Genetic gender change (severe medical, legal and psychosocial problem) was performed in 3 cases, i.e., in 10% of the total number of surgeries (95% CI 3.5 to 25.6%).

Vaginal plastic surgery in female CAH patients due to severe virilization was performed during the first two years of life, clitoris correction: up to the age of 4 years, but the gender change performed at the age of 8 to 10 years.

Laboratory data (immunogenetic and molecular genetic findings)

One part of the study's laboratory work determined the relationship of CAH and its clinical forms with certain HLA locuses in the material of involved patients. It was established that most related to the development of CAH are HLA locuses A3, B60 and Bw51 (18.9% cases each), as well as locuses B14 and Bn47 (15% cases each). When the potential relationship between the above mentioned HLA locuses and the

development of some definite clinical form of CAH was evaluated, there was an impression that the study finding presents an evidence on the possible relationship between HLA locus A1, Bn47 and B60, and the development of the CAH salt loss form, but HLA locuses B14 and Bw51, on their turn, show some relation to the development of the CAH simple virilizing form. HLA locus A3 could be related to the development of both clinical forms of CAH. Potential relationship between the simple virilizing form of CAH and the locus Cw4 can not be excluded as well.

CYP21 gene mutations were tested in the material from patients involved in the second part of the study's laboratory work. Obtained results show that in the evaluated CAH patients group (represented by all Latvian regions) the following *CYP21* gene mutations prevailed:

8-bp deletion in exon 3 and I2G/I2G mutation in intron 2, causing development of CAH salt loss form and

Pro30Leu, Val281Leu, as well as Ile172Asn mutations that in their turn cause development of CAH simple virilizing form; in addition it is known that Pro30Leu is related to the moderate prenatal hypertrophy of clitoris, Val281Leu – to classic CAH form, but Ile172Asn – to the severe prenatal virilization without salt loss.

These observations match to the literature data on the predominant *CYP21* gene mutations in Europe [13, 15, 92, 93] and on the genotype / phenotype correlation in CAH patients.

Pro453Ser, 8bpdel, as well as point type mutations in intron 2 prevail in Central Europe (Austria, Check Republic, Hungary, Slovakia, Slovenia) [20,85,208].

Pro453Ser, 8bpdel and Val281Leu mutations prevail in Northern European region (Sweden, Finland, Denmark) [17,155].

8bpdel and Val281Leu mutations prevail in Sothern Europe (Spain, Italy) (18,19), but in Western Europe (Germany, France, United Kingdom) – in addition to the above mentioned mutations, point type mutations in intron 2 are quite common [73,87,133].

5 years follow-up of clinical course in studied children with CAH

During the longlasting 5 years follow-up of all 53 studied children with CAH connection between clinical manifestation of CAH, laboratory findings and genetical characteristics of *CYP21* gene mutations has been clearly elucidated. Respectively, marked disbalance of electrolytes, elevated level of $17\alpha\text{OHPg}$, development of acute suprarenal insufficiency as a complication observed in patients with salt wasting form of CAH, and typical for this disorder *CYP21* gene mutations – I2G/I2G, I2G/R356W, I2G/del, Q318X/R356W, R356W/R356W, make a certain clinical, laboratory and genetical complex or whole entity.

In the course of study an analyze of data and making conclusions were bothered by several substantial circumstances, respectively, it was not possible to detect a level of $17\alpha\text{OHPg}$ in years 1989 – 1992 and there was not available Hydrocortisonum untill year 1993 in Latvia. Although allowed for use thereafter, Hydrocortisonum periodically was unavailable for patients with CAH because of bad supply and problems to include it in the list of compensated pharmaceuticals. As a result, there were certain difficulties to set appropriate treatment for these patients.

Outpatient controls less frequent than recommended indicate that cooperation of patients in the process of treatment and follow-up was inadequate low.

Analyze of growth allows to conclude that a mean final height in these patients is substantially lower than in average for Latvian population. Although it concerns to both clinical forms of CAH, growth retardation in patients with simple virilizing form

is more pronounced than in patients with salt wasting form, because of later diagnostics of CAH, more longlasting influence of hyperandrogenia on bone epiphyseal growth plates and earlier closure of growth zones.

Analyzing dynamics of growth some following tendencies can be observed. Respectively, during the first year of life growth velocity of CAH affected children is slightly lower (-0.5 ± 0.3 SDS) than that of their healthy peers. Thereafter, up to age of 10 years, growth velocity of children with CAH (regardless the form of CAH or sex of child) uses to be higher than in average for population (0.6 ± 0.3 SDS). During puberty, instead, a progressive growth retardation in case of CAH can be observed and it is more expressed in boys (-1.1 ± 0.5 SDS) than in girls (-0.9 ± 0.4 SDS).

Short final or adult height is one of the most actual problem during treatment of CAH in childhood. In clinical trials and studies there are different attempts to find solution of this problem using combined glucocorticoid treatment with somatotropin, GnRH agonists, antiandrogens, inhibitors of aromatase or bilateral adrenalectomia in case if it is very difficult to reach appropriate CAH compensation [239].

Onset of puberty in boys with CAH usually is earlier than in girls. It means, that in boys undiagnosed simple virilizing form of CAH clinically can manifest as pubertas precox.

Level of $17\alpha\text{OHPg}$ in blood is regarded as one of the basic criteria of CAH compensation. During patients follow-up in this study it is checked that the mean level of $17\alpha\text{OHPg}$ exceeds the interval accepted as compensation ($1.0 - 10.0$ ng/ml) [239, 241]. Mainly it concerns to the period of puberty what allows to conclude, that because of physiological hypersecretion of gonadal androgens an appropriate compensation of CAH at this age it is difficult to reach. Additional factor influencing compensation of this disorder is patients and parents cooperation.

Dosage of glucocorticoids at the age from 1 to 10 years use to be higher in case of salt wasting form, because of elevated risk of hypoglycemia or acute CAH decompensation in early childhood. During puberty, instead, higher dosage of glucocorticoids use to be necessary in case of simple virilizing form because of pubertas precox, hypersecretion of gonadal androgens and increased cortisol clearans at this age [238].

Dosage of mineralocorticoids use to be higher during infancy and up to 2 years of age, because of elevated acute salt wasting risk. The highest dosage of mineralocorticoids usually is necessary up to 3 months of age with gradual decreasing of the dose thereafter.

Acute suprarenal insufficiency as a complication of CAH in studied patients has developed on the background of acute severe intercurrent illnesses at the age of elevated risk for children with CAH. The leading symptom observed in these cases was hypoglycemia. Eventual reasons of lethal cases probably are in delaying to increase the dose of glucocorticoids at home situation and in delaying to start parenteral treatment with glucocorticoids at hospital as well. Certain influence on results in these cases have had an insufficient education of parents to act in critical situations and inappropriate evaluation of child's condition. Compared with published data where stated lethality in patients with salt wasting form of CAH in 4.6%, but severe hypoglycemia in 9% cases [240], lethality observed during follow-up of studied patients is considerably lower (1.06%), but episodes of hypoglycemia – fewer (7.8%).

Early diagnostics of CAH, optimal pharmaceutical and surgical treatment, appropriate and repeated education of parents, regular dynamic follow-up, patients

and parents cooperation help to reach adequate compensation of CAH, avoid acute decompensation of CAH and its complications, provide normal growth, preserve fertility and improve a quality of patients life.

Practical considerations

1. There are different DNA diagnostic methods for determination of mutations that differ by the accuracy, costs of the method and availability of equipment. Known mutations can be established by restriction polymorphism analysis, genotyping methods. For detection of new mutations the most appropriate is sequencing or one strain polymorphism analysis. Method for sequencing of *CYP21* gene has been developed, but the work should be continued on the use of *CYP21* exon sequencing development in routine diagnostics.

2. Complete gene sequencing is expensive method for use in routine diagnostics, however with it help rare and unknown mutations can be found, with exception of large deletions and inversions, which not always can be detected by sequencing. For needs of routine diagnostics less expensive method should be used, which would be capable to detect common mutations, e.g. – genotyping.

3. If it has been found that both mutations are heterozygote, then for confirmation of 21-hydroxylase deficit diagnosis it must be proved that each of these mutations is localized in a separate allele. It could be proved by analysis of parent DNA samples. If these mutations will not be found only in one of parents, then we could consider that they are placed in different alleles and cause CAH.

4. Presence of CAH salt loss form should be excluded in all newborns [208, 209, 216, 91] with:

- Changed external genitals (including severe hyperpigmentation and/or visual cryptorchidism in boys) or unclear gender of the newborn,
- Severe eating disorders, repeated vomiting, weight loss, dehydration,
- Broncho-pulmonal dysplasias, considering possibility of CAH also in case of other type respiratory insufficiency in neonatal period,
- Clinical picture of septicemia without any infectious cause,
- Laboratory finding of adrenocortical insufficiency (first of all – hyperkalemia and hyponatremia “scissors” in routine biochemical examinations).

5. Research data on diagnostics age clearly show that CAH diagnostics in Latvia is on the age of approximately 5.2 months, but in Europe on average by the age of 3 months. Substantiated impression occurs that the cause of such delayed diagnostics is CAH hypodiagnosics. In addition, it is not related only to CAH diagnostics in boys (that is a well known problem in pediatric practice world-wide, as virilization can be noticed in boys only in very severe cases), but also in girls with less severe virilisation signs. It marks the future job – development of wider and deeper information for children, parents and also physicians on CAH, its signs and possible health problems both in childhood and later periods of life of these patients.

6. On the bases of recommendations elaborated by ESPE and *Lawson Wilkins Pediatric Endocrine Society* [214] appropriate CAH diagnostic algorithms have been widely introduced in the world pediatric practice [33, 219]. The following algorithms have been adopted for conditions of Latvia:

- ‘Congenital adrenal hyperplasia manifested during newborn period’ and
- ‘Congenital adrenal hyperplasia manifested following newborn period’.

These algorithms are used also in the Endocrinology center of BKUS as everyday routine, they are used in this research work and can be recommended for any pediatric practice in the country.

7. Conclusions

1. Laboratory finding of HLA locus research indicates:
 - the association of HLA locuses A1, Bn47 and B60 to the development of CAH salt loss form,
 - the association of HLA locuses B14 and Bw51 to the development of CAH simply virilizing form,
 - the association of HLA locus A3 to the development of CAH salt loss and simply virilizing form,
 - the possible association of HLA Cw4 to the CAH simply virilizing form.
2. CAH development HLA types in Latvia do not differ significantly from those in Europe [11,13,91,92].
3. Laboratory finding of CYP21 gene mutation research indicates that the following *CYP21* gene mutations prevail in Latvia:
 - 8-bp deletions in exon 3 and 12G/12G mutations in intron 2 causing development of CAH salt loss form,
 - Pro30Leu, Val281Leu and Ile172Asn mutations causing development of CAH simply virilizing form.
4. Range of *CYP21* gene predominant mutations in CAH patients in Latvia do not differ from that established in the European countries [11,13,91,92].
5. Dynamic analyze of the course of CAH in included in the study children during the 5-years follow-up period up to year 2009 shows that:
 - there is a relevance between clinical and laboratory parameters, development of CAH complications and characteristics of CYP21 gene mutations,
 - adult or final height in patients suffering from any of both CAH forms is considerably shorter than average statistical norm for population; growth retardation is more pronounced in patients with simple virilizing form of CAH,
 - there is an early pubertal development in boys,
 - it is difficult to reach a satisfactory level of CAH compensation during period of puberty,
 - dosage of glucocorticoids at age from 1 to 10 years are higher in case of salt wasting form, but during period of puberty higher doses of glucocorticoids are necessary for patients with simple virilizing form,
 - dosage of mineralocorticoids are highest from birth up to 3 months of age, gradually decreasing thereafter,
 - acute suprarenal insufficiency in studied patients has developed as complication of CAH at high-risk early childhood age on the background of acute severe intercurrent illnesses; the leading symptom observed in these cases was hypoglycemia,

6. Lethality observed during follow-up of studied patients (1.06%) was considerably lower than reported in literature (4.6%); episodes of hypoglycemia observed in CAH patients during this study (7.8%) were fewer compared with published data (9%) as well.

Paper approbation

Paper approbation has been performed in the united meeting of RSU Department of Pediatrics, Latvian Association of Endocrinologists and Latvian Association of Pediatric Endocrinologists on March 4, 2009.

Publications reflecting the Doctorate paper

1. I. Dzīvīte. Iedzimtas virsnieru garozas hiperplāzijas raksturojums Latvijā 1. konference “Bērnu un pusaudžu ginekoloģijas medicīniskie un sociālie aspekti Latvijā un Austrumeiropā”. Tēzes, 4-5, 1996. X, Vaivari
2. I. Dzīvīte. Adrenogenitālais sindroms. Latvijas Ārsts 10, 24 – 27, 1996.
3. I. Dzīvīte. Review of Latvian patients with CAH. Hormone Research 48 (suppl 2), 856-857, 1997.
4. LBPEC uzskaitē esošo iedzimta AGS slimnieku dažu klīnisko un laboratoro datu analīze. Trešā Pasaules Latviešu Ārstu kongresa tēzes, 6, 1997.
5. I. Dzīvīte. 21-hidroksilāzes deficīta molekulārie mehānismi un tā klīniskās un terapeitiskās sekas. Latvijas Ārstu Žurnāls 11, 15 – 19, 1999.
6. I. Dzīvīte. Iedzimta adrenogenitālā sindroma neklasiskās formas daži praktiski aspekti. Aktualitātes diabetoloģijā un endokrinoloģijā 4, 8 – 10, 2002
7. I. Auziņa, I. Dzīvīte, I. Steinberga. Slimnieks ar iedzimtu virsnieru garozas hiperplāziju jeb sievišķo pseidohermafroditismu. Latvijas Ķirurģijas Žurnāls (Acta Chirurgica Latviensis) 83 – 85, 2002, Nr 2
8. I. Dzīvīte, D. Gardovska. Genotipa – fenotipa korelācijas starp 22 21-hidroksilāzes deficīta pacientiem. ZA Raksti / RSU, 134 – 137, 2002
9. I. Dzīvīte. Dzimumdiferenciācijas traucējumi nav kazuistika. Jums kolēģi, 12 – 16, 2003, Nr 1
10. I. Dzīvīte. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Proceedings of Latvian Academy of Sciences. Vol 58 2004, Nr 2, 31 – 38.
11. I. Dzīvīte-Krišāne. 21-hidroksilāzes deficīta molekulārie mehānismi, imūnģenētiskais raksturojums, to klīniskās un terapeitiskās konsekvences bērniem Latvijā. RSU 2010. gada Zinātniskā konference. Tēzes, 133 lpp.
12. I. Dzīvīte-Krisane. Molecular mechanisms, immunogenetic characteristics, clinical and therapeutical consequences of the 21-hydroxylase deficiency in the Latvian children. Proceedings of Latvian Academy of Sciences. 2010 (in press April, 2010).
13. I. Dzīvīte-Krisane. Molecular mechanisms, immunogenetic characteristics, clinical and therapeutical consequences of the 21-hydroxylase deficiency in the Latvian children. Hormone Research in Paediatrics 74(suppl 3), 167, 2010 (abstract).

Reports on the job results

1. Characteristics of hereditary adrenocortical hyperplasia in Latvia. 1st conference “Medical and social aspects of children and adolescents gynecology in Latvia and Eastern Europe”. October 28, 1996, Vaivari.
2. Characteristic of CAH patients. ESPE Winter School, January, 1997, Lezno, Poland.

3. Analysis of some clinical and laboratory data of hereditary AGS patients listed in LBPEC. 3rd Congress of World Latvian Physicians, June 20, 1997, Riga.
4. Review of Latvian patients with CAH. European Society for Pediatric Endocrinology (ESPE) / Lawson Wilkins Pediatric Endocrine Society (LWPES) 5th Joint Meeting. June 4, 1997, Stockholm, Sweden (poster).
5. Characteristics of hereditary adrenocortical hyperplasia in Latvian children. AML BS conference, December, 1999, Riga.
6. Molecular genetic characteristics of Latvian CAH patients. Congress of Swedish Society of Endocrinologists, October 15, 2001, Goteborg, Sweden.
7. Immunogenetic analysis of CAH patients in Latvia. Conference of Pediatrics clinics of the Free University of Amsterdam, April 10, 2002, Amsterdam, the Netherlands.
8. Hereditary hyperplasia of adrenal cortex, Conference of Latvian Society of Endocrinologists, November, 2002, Riga.
9. Molecular mechanisms of 21-hydroxylase deficiency and its clinical consequences in Latvian children. Conference of Baltic Pediatric Endocrinologists, May 3, 2005, Vaivari.
10. 21-hydroxylase deficiency in Latvia. Conference of Association of Pediatric Endocrinologists, September 26, 2006, Kaunas, Lithuania.
11. CAH as a cause of short stature. 3rd Postgraduate Training Courses of the European Society of Pediatric Endocrinology on March 24, 2007 in Ohrid, Macedonia.
12. I.Dzivite-Krisane. Molecular mechanisms, immunogenetic characteristics, clinical and therapeutical consequences of the 21-hydroxylase deficiency in the Latvian children. RSU Scientific conference. 19 March, 2010. Poster presentation.
13. I.Dzivite-Krisane. Molecular mechanisms, immunogenetic characteristics, clinical and therapeutical consequences of the 21-hydroxylase deficiency in the Latvian children. European Society for Paediatric Endocrinology (ESPE). 22 - 25 September, 2010, Prague. Poster presentation.

Appreciations

Thank you very much to my parents – Talivaldis Ciekurzis and Vizma Dzivite, to my husband and daughters. Without their belief in my target, my ideas, without their support and facilitation of everyday activities this job would not be possible.

I would like to express my gratitude most of all to the manager of my job professor Dace Gardovska for ideas, encouragement, sincerity, patience and support, as well as to my scientific consultant Edvins Miklasevics for responsiveness, valuable advices and healthy critics.

Thank you very much to my teachers in the difficult discipline of pediatric endocrinology – Mara Arente, professor Martin Ritzen in the Karolinska Institute in Stockholm. I had an honour and luck to learn under his guidance for a long-term, and he made a large contribution to help me in realization of the experimental part of my job, as well as to professor Henriette Delemarre van de Waal in Amsterdam.

I am sending my appreciation words to my supporters and advisers in Stockholm – professor Martin Ritzen, professor Anna Wedel, Svetlana Lajic, professor Olle Soder and associate professors Mikael Holst and Lars Hagenaaas.

Thank you to my colleagues Inara Kirillova, Una Lauga and all colleagues in my department for friendly support, reassurance, assistance, ideas, thoughts, collegiality and patience throughout the long making period of this job. Thanks a lot to all nurses for hard practical help.

I would like to express my gratitude to professor Uldis Teibe for his great help in searching proper way in difficult labyrinth of statistics.

Thank you to all children and their parents taking part in the study.

In conclusion I would like to thank the Swedish Institute and European Society of Pediatric Endocrinology for financial support.

References

1. Crecchio D. Sopra un caro di apparenzi virili in una donna. Morgagni 1865;7:154-188
2. Wilkins L., Levis R. and Rosenberg E. The suppression of androgen secretion by cortizone in a case of congenital adrenal hyperplasia. Bull Johns Hap 1950;86:249-252
3. White Perrin C. and Speiser Phyllis W. Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Endocrine Review 2000;21:245-291
4. Speiser Phyllis W. Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Endocrinology and Metabolism Clinics North America 2001;1:31-59
5. Migeon Claude J. and Wisniewski Amy B. Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Endocrinology and Metabolism Clinics North America 2001;1:193-205
6. New Maria I. Prenatal Treatment of Congenital Adrenal Hyperplasia. Endocrinology and Metabolism Clinics North America 2001;1:1-13
7. Merke Deborah P. and Cutler Gordon B. New Ideas for Medical Treatment of Congenital Adrenal Hyperplasia. Endocrinology and Metabolism Clinics North America 2001;1:121-135
8. Chin Daisy, Speiser Phyllis W., Imperato-McGinley Julianne et al. Study of a Kindred with Classic Congenital Adrenal Hyperplasia: Diagnostic Challenge due to Phenotypic Variance. J Clin Endocrinol Metab 1998;83:1940-1945
9. Acerini Carlo L., Hughes Ieuan A. 21-Hydroxylase Deficiency Defects and Their Phenotype. In: Adrenal Disease in Childhood. Clinical and Molecular Aspects. Endocr. Dev. Basel, Karger, 2000, vol 2, pp 93-111
10. Speiser Phyllis W., Knochenhauer Eric S, Dewailly Didier et al. A multicenter Study of Women with Nonclassical Congenital Adrenal Hyperplasia: Relationship between Genotype and Phenotype. Molecular Genetics and Metabolism 2000;71:527-534
11. Rumsby G, Averyt CJ, Conway GS and Honour JW. Genotype-phenotype analysis in late onset 21-hydroxylase deficiency in comparison to the classical forms. Clinical Endocrinology 1998;48:707-711
12. Charmandari E, Lichtarowicz-Krynska EJ, Hindmarsh PC. et al. Congenital adrenal hyperplasia: management during critical illness. Arch Dis Child 2001;85:26-28
13. Jaaskelainen J. and Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr 2000;89:183-187
14. Moran Carlos, Azziz Ricardo, Carmina Enrico et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study. Am J Obstet Gynecol 2000;183:1468-1474
15. Wedell A. Molecular genetics of Congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. Acta Paediatr 1998;87:159-164
16. Higashi Yujiro, Hiromasa Takako, Tanae Ayako et al. Effects of Individual Mutations in the P-450 (C21) Pseudogene on the P-450 (C21) Activity and Their Distribution in the Patient Genomes of Congenital Steroid 21-Hydroxylase Deficiency. J Biochem 1991;109:638-644
17. Wedell A, Thilen A, Ritzen EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994;178:1145-1152
18. Ezquieta B, Oliver A, Gracia R, et al. Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Hum Genet 1995;96:198-204
19. Dracopoulou-Vabuoli M., Maniati-Christidi M., Dacou-Voutetaki C. The spectrum of molecular defects of the CYP21 gene in the Hellenic population. J Clin Endocrinol Metab 2001;86:2845-2849

20. Baumgartner-Parzer SM, Schulze E, Waldhausl W, et al. Mutational Spectrum of the Steroid 21-Hydroxylase Gene in Austria: Identification of a Novel Missense Mutation. *J Clin Endocrinol Metab* 2001;86:4771-4775
21. Krone Nils, Roscher Adelbert Anton, Schwarz Hans Peter and Braun Andreas. Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. *Clin Chem* 1998;44:2075-2082
22. Oriola J, Plensa I, Machuka I, et al. Rapid screening method for detecting mutations in the 21-hydroxylase gene. *Clin Chem* 1997;43:557-561
23. Lee HH, Chao HH, Ng HAT, Choo KB. Direct molecular diagnosis of CYP21 mutations in Congenital adrenal hyperplasia. *J Med Genet* 1996;33:371-375
24. Olney Robert C., Mougey Edward B., Wang Jianwei et al. Using Real-Time, Quantitative PCR for rapid Genotyping of the Steroid 21-Hydroxylase Gene in a North Florida Population. *J Clin Endocrinol Metab* 2002;87:735-741
25. Owerbach D, Draznin MB, Carpenter RJ, Greenberg F. Prenatal diagnosis of 21-hydroxylase deficiency using the polymerase chain reaction. *Hum Genet* 1992;89:109-110
26. Honour JW, Torresani T. Evaluation of neonatal screening for Congenital adrenal hyperplasia. *Horm Res* 2001;55(4):201-205
27. Krone N, Wachter I, Stefanidou M, Roscher AA, Schwarz HP. Mothers with Congenital adrenal hyperplasia and their children : outcome of pregnancy, birth and childhood. *Clin Endocrinol* 2001;55 (4):523-529
28. Loke KY, Lee YS, Lee WW, Poh LK. Molecular analysis of CYP-21 mutations for Congenital adrenal hyperplasia in Singapore. *Horm Res* 2001;55 (4):179-184
29. Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. "TT"Serum cortisol and 17-hydroxyprogesterone interrelation in classical 21-hydroxylase deficiency : is current replacement therapy satisfactory ? *J Clin Endocrinol Metab* 2001;86(10):4679-4685
30. Hargitai G, Solyom J, Battelino T, et al. Growth patterns and final height in Congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of multicenter study. *Horm Res* 2001;55(4):161-171
31. Nordenstrom A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for Congenital adrenal hyperplasia : 17-hydroxyprogesterone levels and CYP-21 genotypes in preterm infants. *Pediatrics* 2001;108 (4):E68
32. Merke D, Kabbani M. Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment. *Paediatr Drugs* 2001;3(8):599-611
33. Nimkarn S, New MI. Prenatal diagnosis and treatment of Congenital adrenal hyperplasia. *Horm Res* 2007;67(2):53-60
34. David M, Forest MG. Prenatal treatment of Congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. *J Pediatr* 1984;105:799-803
35. Jeffcoate TN, Fliegner JR, Russell SH, Davis JC, Wade AP. Diagnosis of the adrenogenital syndrome before birth. *Lancet* 1965;2:553-555
36. Frasier SD, Thorneycroft IH, Weiss BA, Horton R. Elevated amniotic fluid concentration of 17 alpha-hydroxyprogesterone in Congenital adrenal hyperplasia. *J Pediatr* 1975;86:310-312
37. Marcus ES, Holcombe JH, Tulchinsky D, Rich RR, Riccardi VM. Prenatal diagnosis of Congenital adrenal hyperplasia. *Am J Med Genet* 1979;4:201-204
38. Speiser PW, Laforgia N, Kato K. First trimester prenatal treatment and molecular genetic diagnosis of Congenital adrenal hyperplasia (21-hydroxylase deficiency). *J Clin Endocrinol Metab* 1990;70:838-848
39. American Academy of Pediatrics, Section of Endocrinology and Committee on Genetics. Technical Report: Congenital Adrenal Hyperplasia. *Pediatrics* 2000; 106:1511-1518

40. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1977;45:1003-1008
41. Therrell BL, Berenbaum SA, Manter-Kapanke V. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient Congenital adrenal hyperplasia. *Pediatrics*. 1998;101:583-590
42. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A Improved precision of newborn screening for Congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. *J Pediatr* 1997;130:128-133
43. Dixit N, Torresani T, Speiser PW. Genotyping CYP21 as an adjunct to hormonal screening of newborns for CAH. In. *Programs and Abstracts*. New Orleans, LA: The Endocrine Society; 1998;. Abstract P2-151
44. Pang S, Shook MK Current status of neonatal screening for Congenital adrenal hyperplasia. *Curr Opin Pediatr* 1997;9:419-423
45. al Saedi S, Dean H, Dent W, Stockl E, Cronin C Screening for Congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. *Pediatrics* 1996;97:100-102
46. Newborn Screening Committee, The Council of Regional Network for Genetic Services (CORN). *National Newborn Screening Report, 1994*. Atlanta, GA: The Council of Regional Network for Genetic Services; January 1999:118-133
47. Gotoh H, Kusakabe M, Shiroishi T, Moriwaki K. Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of Congenital adrenal hyperplasia in humans. *Endocrinology* 1994;135:1470-1476
48. Tajima T, Okada T, Ma X, Ramsey W, Bornstein S, Aguilera G. Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochromeP450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. *Gene Ther* 1999;6:1898-1903
49. Miller WL, Chrousos GP. The adrenal cortex. In Felig P, Frohman L (eds): *Endocrinology and Metabolism*, 4th ed. New York, McGraw-Hill, 2001, 385-524
50. Wilson RC, Wei JQ, Cheng KC, Mercado AB, New MI. Rapid DNA analysis by allele-specific PCR for detection of mutations in the steroid 21-hydroxylase gene. *J Clin Endocrinol Metab* 1995;80:1635-1640.
51. White PC, New MI. Molecular genetics of Congenital adrenal hyperplasia. *Baillieres Clin Endocrinol Metab* 1988 2:941-965
52. Yang YP, Corley N, Garcia-Heras J. Reverse dot-blot hybridization as an improved tool for the molecular diagnosis of point mutations in Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. *Mol Diagn* 2001;6(3):193-199
53. Hernanz-Schulman M, Brock JW, Russel W. Sonographic findings in infants with Congenital adrenal hyperplasia. *Pediatr Radiol* 2002;32(2):130-137
54. Witchel SF, Smith R, Crivellaro CE, et al. CYP21 mutations in Brazilian patients with 21-hydroxylase deficiency. *Hum Genet* 2000;106(4):414-419
55. Wudy SA, Hartmann M, Homoki J. Hormonal diagnosis of 21-hydroxylase deficiency in plasma and urine of neonates using benchtop gas chromatography-mass spectrometry. *J Endocrinol* 2000;165(3):679-683
56. Root AM. Neonatal screening for 21-hydroxylase deficient Congenital adrenal hyperplasia - the role of CYP21 analysis. *J Clin Endocrinol Metab* 1999;84(5):1503-1504
57. Merke DP, Bornstein SR, Braddock D, Chrousos GP. Adrenal lymphocytic infiltration and adrenocortical tumors in a patient with 21-hydroxylase deficiency. *N Engl J Med* 1999;340(14):1121-1122

58. Levo A, Jaaskelainen J, Sistonen P, Siren MK, Voutilainen R, Partanen J. Tracing past population migrations: genealogy of steroid 21-hydroxylase (CYP21) gene mutations in Finland. *Eur J Hum Genet* 1999;7(2):188-196
59. Bachega TA, Billerbeck AE, Madureira G, et al. Low frequency of CYP21B deletions in Brazilian patients with Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Hum Hered* 1999;49(1):9-14
60. Lai C, Tsai C, Tsai F, Wu J, Lin W, Lee C. Rapid screening assay of Congenital adrenal hyperplasia by measuring 17-alpha-hydroxyprogesterone with high performance liquid chromatography / electrospray ionization tandem mass spectrometry from dried blood spots. *J Clin Lab Anal* 2002;16(1):20-25
61. Bachega TA, Brenha EM, Billerbeck AE, et al. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations. *J Clin Endocrinol Metab* 2002;87(2):786-741
62. Gmyrek GA, New MI, Sosa RE, Poppas DP. Bilateral laparoscopic adrenalectomy as a treatment for classical Congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. *Pediatrics* 2002;109(2):E28
63. Nordenstrom A, Servin A, Bohlin G, Larsson A, Wedell A. Sex-typed toy play behavior correlates with the degree of prenatal androgen exposure assessed by CYP21 genotype in girls with Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2002;87:5119-5124
64. Merke DP, Fields JD, Keil MF, Vaituzis AC, Chrousos GP, Giedd JN. Children with classic Congenital adrenal hyperplasia have decreased amygdala volume: potential prenatal and postnatal hormonal effects. *J Clin Endocrinol Metab* 2003;88:1760-1765
65. Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2003;88:1102-1106
66. Levo A, Partanen J. Novel mutations in the human CYP21 gene. *Prenat Diagn* 2001;21(10):885-889
67. New MI, Carlson A, Obeid J, Marshall I, et al. Prenatal diagnosis for Congenital adrenal hyperplasia in 532 pregnancies. *J Clin Endocrinol Metab* 2001;86(12):5651-5657
68. Nordenstrom A, Marcus C, Axelson M, Wedell A, Ritzen EM. Failure of cortisone acetate treatment in Congenital adrenal hyperplasia because of defective 11-beta-hydroxysteroid dehydrogenase reductase activity. *J Clin Endocrinol Metab* 1999;84(4):1210-1213
69. Witchel SF, Smith R, Suda-Hartman M. Identification of CYP 21 mutations by single strand conformational polymorphism (SSCP) analysis. *Hum Mutat* 1999;13(2):172
70. Wei WL, Killeen AA. Analysis of four common salt-wasting mutations in CYP21 (steroid 21-hydroxylase) by cleavage fragment length polymorphism analysis and characterization of a frequent polymorphism in Intron 6. *Mol Diagn* 1998;3(3):171-177
71. Lo J.C., Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1999;84(3):930-936
72. Lako M, Ramsden S, Campbell RD, Strachan T. Mutation screening in British 21-hydroxylase deficiency families and development of novel microsatellite based approaches to prenatal diagnosis. *J Med Genet* 1999;36(2):119-124
73. Garner PR. Congenital adrenal hyperplasia in pregnancy. *Semin Perinatol* 1998;22(6):446-456
74. Speiser PR, White PC. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. *Clin Endocrinol* 1998;49(4):411-417
75. Lopez-Gutierrez AU, Riba L, Ordonez-Sanchez ML, et al. Uniparental disomy for chromosome 6 results in steroid 21-hydroxylase deficiency: evidence of different genetic mechanisms involved in the production of the disease. *J Med Genet* 1998;35(12):1014-1019
76. Moran C, Knochenhauer ES, Azziz R. Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. *J Endocrinol Invest* 1998;21(10):707-720

77. Killeen AA, Jiddou RR, Sane KS. Characterization of frequent polymorphisms in Intron 2 of CYP21: application to analysis of segregation of CYP21 alleles. *Clin Chem* 1998;44(12):2410-2415
78. Wedell A. An update on the molecular genetics of Congenital adrenal hyperplasia: diagnostic and therapeutic aspects. *J Pediatr Endocrinol Metab* 1998;11(5):581-589
79. Lajic S, Wedell A, Bui TH, Ritzen EM, Holst M. Long - term somatic follow-up of prenatally treated children with Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1998;83(11):3872-3880
80. Erel CT, Senturk LM, Oral E, Colgar U, Ertungealp E. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. *Gynecol Endocrinol* 1998;12(4):223-229
81. Tajima T, Fujieda K, Mikami A, Igarashi Y, Nakae J, Cutler GB Jr. Prenatal diagnosis of steroid 21-hydroxylase deficiency by the modified polymerase chain reaction to detect splice site mutation in the CYP21 gene. *Endocr J* 1998;45(3):291-295
82. Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC, et al. Worldwide experience in newborn screening for classical Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Pediatrics* 1988;81:866-874
83. Lajic S, Nordenstrom A, Ritzen EM, Wedell A. Prenatal treatment of Congenital adrenal hyperplasia. *Eur J Endocrinol* 2004;151(suppl 3):U63-U69
84. Dolzan V, Solyom J, Fekete G, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with Congenital adrenal hyperplasia. *Eur J Endocrinol* 2005;153:99-106
85. Friaes A, Rego AT, Aragues JM, et al. CYP21A2 mutations in Portuguese patients with Congenital adrenal hyperplasia: identification of two novel mutations and characterization of four partial gene conversions. *Mol Genet Metab* 2006;88:58-65
86. Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, et al. CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations. *J Clin Endocrinol Metab* 2003;88:3852-3859
87. Miller WL, Levine LS. Molecular and clinical advances in Congenital adrenal hyperplasia. *J Pediatrics* 1987;111:1-16
88. Vilee DB. The development of steroidogenesis. *Am J Med* 1972;53:533-544
89. Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC. Fetal sex determination from maternal plasma in pregnancy at risk for Congenital adrenal hyperplasia. *Obstet Gynecol* 2001;98:374-378
90. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. *N Engl J Med* 2002;346:1502
91. Bajpai A, Kabra M, Menon PSN. 21-hydroxylase deficiency: clinical features, laboratory profile and pointers to diagnosis in Indian children. *Indian Pediatrics* 2004;41:1226-1232
92. Osinovskaya NS, Ivashchenko TE, Baranov VS. Analysis of the association between the HLA-DQA1 alleles and the steroid 21-hydroxylase gene mutations in the patients with Congenital adrenal hyperplasia. *Russian Journal of Genetics* 2004;40(1):81-85
93. Turowski G, Gieracka-Pazucha D, Turowska-Heydel D, Pietrzyk JJ. Soluble HLA-A and HLA-B antigens in children with Congenital adrenal hyperplasia (CAH) and the classical form of 21-hydroxylase deficiency. *Med Sci Monit* 1998;4(4):633-639
94. White PC, Chaplin DD, Weis JH, Dupont B, New MI, Seidman JG . Two steroid 21-hydroxylase genes are located in the murine S region. *Nature* 1984; 312: 465-467
95. White PC, New MI, Dupont B. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. *Proc Natl Acad Sci USA* 1984; 81: 7505-7509

96. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. *Proc Natl Acad Sci USA* 1985; 82: 1089-1093
97. Rich MA, Keating MA, Levin HS, Kay R. Tumors of the adrenogenital syndrome: an aggressive conservative approach. *J Urol* 1998;160(5):1838-1841
98. Toth M, Racz K, Glaz E. Increased plasma 17-hydroxyprogesterone response to ACTH in patients with non-hyperfunctioning adrenal adenomas is not due to a deficiency in 21-hydroxylase activity. *J Clin Endocrinol Metab* 1998;83(10):3756-3757
99. Gell JS, Carr BR, Sasano H, Atkins B, Margraf L, Mason JI, Rainey WE. Adrenarche results from development of 3-beta-hydroxysteroid dehydrogenase-deficient adrenal reticularis. *J Clin Endocrinol Metab* 1998;83(10):3695-3701
100. Tajima T, Okada T, Ma XM, Ramsey W, Bornstein S, Aguilera G. Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P540 21-hydroxylase into the adrenal gland of 21-hydroxylase deficient mice. *Gene Ther* 1999;6(11):1898-1903
101. Spiro RP, Christian SL, Ledbetter DH, New MI, Wilson RC, Roizen N, Rosenfield RL. Intrauterine growth retardation associated with maternal uniparental disomy for chromosome 6 unmasked by adrenal hyperplasia. *Pediatr Res* 1999;46(5):510-513
102. Huerta R, Dewailly D, Decanter C, Knochenbauer ES, Boots LR, Azziz R. 11-beta-hydroxyandrostendione and delta-5-androstendiol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient non-classic adrenal hyperplasia. *Fertil Steril* 1999;72(6):996-1000
103. Cohen MA, Sauer MV, Lindheim SR. 21-hydroxylase deficiency and Turner's syndrome: a reason for diminished endometrial receptivity. *Fertil Steril* 1999;72(5):937-939
104. Azziz R, Hincapie LA, Knochenbauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. *Fertil Steril* 1999;72(5):915-925
105. New MI, Wilson RC. Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess. *Proc Natl Acad Sci U.S.A.* 1999;96(22):12790-12797
106. Escobar-Morreale HF, San Millan JL, Smith RR, Sancho J, Witchel SE. The presence of the 21-hydroxylase deficiency carrier status in hirsute women : phenotype-genotype correlations. *Fertil Steril* 1999;72(4):629-638
107. Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to Congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. *Fertil Steril* 1987;47:664-670.
108. Klingensmith G, Wentz A, Meyer W, Migeon C. Gonadotropin output in Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1976;43:933
109. Cabrera M, Vogiatzi M, New M. Long term outcome in adult males with classic Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86:3070-3078
110. Moore G, Lacroix A, Rabin D, McKenna T. Gonadal dysfunction in adult men with Congenital adrenal hyperplasia. *Acta Endocrinol* 1980;95:185-193
111. Stikkelbroeck N, Otten B, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86:5721-5728
112. Ghali I, David M, David L. Linear growth and pubertal development in treated Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Clin Endocrinol* 1977;6:425-436
113. Urban M, Lee P, Migeon C. Adult height and fertility in men with Congenital virilizing adrenal hyperplasia. *New Engl J Med* 1978;299:392
114. Valentino R, Savastano S, Tommaselli A, et al. Success of glucocorticoid replacement therapy on fertility in two adult males with 21-CAH homozygote classic form. *J Endocrinol Invest* 1997;20:690-694

115. Molitor J, Chertow B, Fariss B. Long-term follow-up of a patient with Congenital adrenal hyperplasia and failure of testicular development. *Fertil Steril* 1973;24:319
116. Blumberg-Tick J, Boudou P, Nahoul K, Schaison G. Testicular tumors in Congenital adrenal hyperplasia: steroid measurements from adrenal and spermatic veins. *J Clin Endocrinol Metab* 1991;73:1129-1133
117. Cutfield R, Bateman J, Odell W. Infertility caused by bilateral testicular masses secondary to Congenital adrenal hyperplasia (21-hydroxylase deficiency). *Fertil Steril* 1983;40:809-814
118. Rutgers J, Young R, Scully R. The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. *Am J Surg Pathol* 1988;12:503-513
119. Combes-Moukhovsky M, Kottler M, Valensi P, Boudou P, Sibony M, Attali J. Gonadal and adrenal catheterization during adrenal suppression and gonadal stimulation in a patient with bilateral testicular tumors and Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1994;79:1390-1394
120. Radfar N, Barter F, Easley R, Kolins J, Javadpour N, Sherins R. Evidence for endogenous LH suppression in a man with bilateral testicular tumors and Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1977;45:1194-1204
121. Kuhnle U, Land M, Ulick S. Evidence for the secretion of an antimineralocorticoid in Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1986;62:934-940
122. Kowarski A, Finkelstein J, Spaulding J, Holman G, Migeon C. Aldosterone secretion rate in Congenital adrenal hyperplasia. A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. *J Clin Invest* 1965;44:505
123. Rose L, Newmark S, Strauss J, Pochi P. Adrenocortical hydroxylase deficiencies in acne vulgaris. *J Invest Dermatol* 1976;66:324-326
124. Lucky A, Rosenfield R, McGuire J, Rudy S, Helke J. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. *J Clin Endocrinol Metab* 1986;62:840-848
125. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1996;81:3535-3539
126. Merke D, Keil M, Jones J, Fields J, Hill S, Cutler G. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2000;85:1114-1120
127. Merke D, Cutler G. New ideas for medical treatment of Congenital adrenal hyperplasia. *Endocrinol Metab Clin North Am* 2001;30:121-135
128. Speiser PW, Laforgia N, Kato K, et al. First trimester prenatal treatment and molecular genetic diagnosis of Congenital adrenal hyperplasia (21-hydroxylase deficiency). *J Clin Endocrinol Metab* 1990;70:838-848
129. Josso N. Anatomy and endocrinology of fetal sex differentiation. In: DeGroot L, Jameson J, eds. *Endocrinology*. Vol. 3. Philadelphia: W.B. Saunders Company, 2001:1947-1954
130. Forest MG, Betuel H, David M. Prenatal treatment in Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Update 88 of the French multicentric study. *Endocr Res* 1989;15:277-301.
131. Seckl J, Miller W. How safe is long-term prenatal glucocorticoid treatment? *JAMA* 1997;277:1077-1079
132. Forest M, Betuel H, David M. Prenatal treatment in Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. *Endocr Res* 1989;15:277-301.

133. Mercado AB, Wilson RC, Cheng KC, Wei JQ, New MI. Extensive personal experience: Prenatal treatment and diagnosis of Congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1995;80:2014-2020.
134. Forest MG, David M, Morel Y. Prenatal diagnosis and treatment of 21-hydroxylase deficiency. [Review]. *J Steroid Biochem Molec Biol* 1993;45:75-82
135. Gotoh H, Kusakabe M, Shiroishi T, Moriwaki K. Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of Congenital adrenal hyperplasia in humans. *Endocrinology* 1994;135:1470-1476
136. Barker DJP, Byll AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. *BMJ* 1990;301:259-262.
137. Whincup PH, Cook D, Papacosta O, Walker M. Birth weight and blood pressure: cross-sectional and longitudinal relations in childhood. *BJM* 1995;311:773-776.
138. Barker D, Osmond C, Simmonds S, Wield G. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. *BMJ* 1993;306:422-426.
139. Barker D. Fetal origins of coronary heart disease. *BMJ* 1995;311:171-174.
140. Barker DJP, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;341:938-941
141. Trautman PD, Meyer-Bahlburg HF, Postelnek J, New MI. Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. *Psychoneuroendocrinology* 1995;20:439-449
142. Kadair RG, Block MB, Katz FH, Hofeldt FD. 'Masked' 21-hydroxylase deficiency of the adrenal presenting with gynecomastia and bilateral testicular masses. *Am J Med* 1977;62:278-282
143. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1992;74:685-689
144. Beuschlein F, Schulze E, Mora P, Gensheimer HP, Maser-Gluth C, Allolio B, Reincke M. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. *J Clin Endocrinol Metab* 1998;83:2585-2588
145. Kawaguchi H, O'hUigin C, Klein J. Evolutionary origin of mutations in the primate cytochrome P450c21 gene. *Am J Hum Genet* 1992;50:766-780
146. Miller WL. Congenital adrenal hyperplasias. *Endocrinol Metab Clin North Am* 1991;20:721-49
147. Miller WL, Strauss JF 3rd. Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. *J Steroid Biochem Mol Biol* 1999 Apr-Jun; 69(1-6): 131-41
148. Miller WL: Congenital adrenal hyperplasia in the adult patient. *Adv Intern Med* 1999; 44: 155-73
149. Migeon CJ, Donohoue PA. Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. *Endocrinol Metab Clin North Am* 1991;20:277-96
150. Cutler GB Jr, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *N Engl J Med* 1990;323:1806-13
151. New MI. Genetic disorders of adrenal hormone synthesis. *Horm Res* 1992;37(suppl 3):22-33
152. Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. *Crit Rev Clin Lab Sci* 1999;36(4):329-63
153. Amor M, Parker KL, Globerman H, New MI, White PC. Mutation in the CYP21B gene (ile172-to-asn) causes steroid 21-hydroxylase deficiency. *Proc Nat Acad Sci* 1988;85:1600-1604

154. Partanen J, Campbell RD. Substitution of ile172-to-asn in the steroid 21-hydroxylase B (P450c21B) gene in a Finnish patient with the simple virilizing form of Congenital adrenal hyperplasia. *Hum Genet* 1991;87:716-720
155. Wedell A, Ritzen EM, Haglund-Stengler B, Luthman H. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. *Proc Nat Acad Sci* 1992;89:7232-7236
156. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC. Disease expression and molecular genotype in Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Invest* 1992;90:584-595
157. Speiser PW, New MI, White PC. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1. *New Engl J Med* 1988;319:19-23
158. Speiser PW, New MI, White PC. Clinical and genetic characterization of nonclassic 21-hydroxylase deficiency. *Endocr Res* 1989;15:257-276
159. Mornet E, Crete P, Kuttann F, Raux-Demay MC, Boue J, White PC, Boue A. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. *Am J Hum Genet* 1991;48:79-88
160. Ezquieta B, Oliver A, Gracia R, Gancedo PG. Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. *Hum Genet* 1995;96:198-204
161. White PC, Tusie-Luna MT, New MI, Speiser PW. Mutations in steroid 21-hydroxylase (CYP21). *Hum Mutat* 1994;3:373-378
162. Beuschlein F, Schulze E, Mora P, Gensheimer HP, Maser-Gluth C, Allolio B, Reincke M. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. *J Clin Endocrinol Metab* 1998;83:2585-2588
163. Chiou SH, Hu MC, Chung B. A missense mutation at ile172-to-asn or arg356-to-trp causes steroid 21-hydroxylase deficiency. *J Biol Chem* 1990;265:3549-3552
164. Tajima T, Fujieda K, Nakae J, Toyoura T, Shimozawa K, Kusuda S, Goji K, Nagashima T, Cutler GB Jr. Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan. *J Clin Endocrinol Metab* 1997;82:2350-2356
165. Tusie-Luna MT, Speiser PW, Dumic M, New MI, White PC. A mutation (pro30-to-leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. *Molec Endocr* 1991;5:685-692
166. Owerbach D, Crawford YM, Draznin MB. Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification. *Molec Endocr* 1990;4:125-131
167. Higashi Y, Tanae A, Inoue H, Hiromasa T, Fujii-Kuriyama Y. Aberrant splicing and missense mutations cause steroid 21-hydroxylase (P-450[C21]) deficiency in humans: possible gene conversion products. *Proc Nat Acad Sci* 1988;85:7486-7490
168. Miller WL. Gene conversions, deletions and polymorphisms in Congenital adrenal hyperplasia. *Am J Hum Genet* 1988;42:4-7
169. Ezquieta B, Cueva E, Oyarzabal M, Oliver A, Varela JM, Jariego C. Gene conversion (655G splicing mutation) and the founder effect (ghn318-to-stop) contribute to the most frequent severe point mutations in Congenital adrenal hyperplasia (21-hydroxylase deficiency) in the Spanish population. *Clin Genet* 2002;62:181-188
170. White PC, Vitek A, Dupont B, New MI. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. *Proc Nat Acad Sci* 1988;85:4436-4440,
171. White PC, New MI, Dupont B. Structure of the human steroid 21-hydroxylase genes. *Proc Natl Acad Sci USA* 1986;83:5111-5115
172. Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific, and rapid technique. *Tissue Antigens* 1991;37:197-204

173. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and genuine gene. *Proc Natl Acad Sci USA* 1986;83:2841-2845
174. Yu CY. The complete exon-intron structure of a human complement C4A gene. DNA sequences polymorphism, and linkage to the 21-hydroxylase gene. *J Immunol* 1991;146:1057-1066
175. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL. Two genes encoding 21-hydroxylase are located near the genes encoding the fourth component of complement in man. *Proc Natl Acad Sci USA* 1985;82:1089-1093
176. Holler W, Scholz S, Knorr D, Bildingmaier F, Albert ED. Genetic differences between the salt-wasting, simple virilizing, and non-classical types of Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1985;60:757-763
177. Takemori S, Kominami S. The role of cytochrome P450 in adrenal steroidogenesis. *TIBS* 1984;393-396
178. Waterman MR, Simpson ER. Regulation of the biosynthesis of cytochromes P450 involved in steroid hormone synthesis. *Mol Cell Endocrinol* 1985;39:81-89
179. Kimura T. ACTH stimulation on cholesterol side chain cleavage activity of adrenocortical mitochondria. *Mol Cell Biochem* 1981;36:105-122
180. Voutilainen R, Tapanainen J, Chung B, et al. Hormonal regulation of P450_{sc} (20,22 desmolase) and P450_{c17} (17-hydroxylase / 17,20 - lyase) in cultured human granulosa cells. *J Clin Endocrinol* 1986;63:202-207
181. Voutilainen R, Miller WL. Coordinate tropic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side chain cleavage enzyme, P450_{sc}, in human stereogenic tissues. *Proc Natl Acad Sci USA* 1987;84:1590-1594
182. Chung B, Matteson K, Voutilainen R, et al. Human cholesterol side-chain cleavage enzyme, P450_{sc}: cDNA cloning, assignment of the gene to chromosome 15, and expression in the placenta. *Proc Natl Acad Sci* 1986;83:8962-8966
183. Matteson K, Chung B, Urdea MS, et al. Study of cholesterol side-chain cleavage (20,22 desmolase) deficiently causing Congenital lipoid adrenal hyperplasia using bovine sequence P450_{sc} oligodeoxyribonucleotide probes. *Endocrinology* 1986;118:1296-1305
184. Yanagibashi K, Haniu M, Shively JE, et al. The synthesis of aldosterone by adrenal cortex: two zones (fasciculata and glomerulosa) possess one enzyme for 11-beta-, 18-hydroxylation, and aldehyde synthesis. *J Biol Chem* 1986;261:3556-3562
185. Curnow KM, Tusie-Luna M-T, Pascoe L, et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. *Mol Endocrinol* 1991;5:1513-1522
186. Pascoe L, Curnow KM, Slutsker L, et al. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyl oxidase II deficiency. *Proc Natl Acad Sci USA* 1992;89:4996-5000
187. Kawamoto T, Mitsuuchi Y, Toda K, et al. Role of steroid 11-beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. *Proc Natl Acad Sci USA* 1992;89:1458-1462
188. Clark PA. Nonclassic 11-beta-hydroxylase deficiency: report of two patients and review. *J Pediatr Endocr Metab* 2000;13:105-109
189. Hampf M, Dao NTN, Hoan NT, Bernhardt R. Unequal crossing-over between aldosterone synthase and 11-beta-hydroxylase genes causes Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86:4445-4452
190. Geley S, Kapelari K, Johrer K, Peter M, Glatzl J, Vierhapper H, Schwarz S, Helmberg A, Sippell WG, White PC, Kofler R. CYP11B1 mutations causing Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. *J Clin Endocrinol Metab* 1996;81:2896-2901

191. Lin D, Sugawara T, Strauss Jr, Clark BJ, Stocco DM, Saenger P, Rogol A and Miller WL. 1995 Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. *Science* 1995;267:1821-1831
192. Bose H, Sugawara T, Strauss Jr and Miller WL. The pathophysiology and genetics of Congenital lipid adrenal hyperplasia. *International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med* 1996;335:1870-1878
193. Stocco D and Clark B. The role of the steroidogenic acute regulatory protein in steroidogenesis. *Steroids* 1997;62:29-36
194. Miller WL, Strauss Jr. Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. *J Steroid Biochem Mol Biol* 1999;69(1-6):131-41
195. Chung B, Picado-Leonard J, Haniu M, et al. Cytochrom P450c17 (steroid 17-alpha-hydroxylase/17,20 lyase): Cloning of human adrenal and testis cDNA indicates the same gene is expressed in both tissues. *Proc Natl Acad Sci USA* 1987;84:407-411
196. Matteson KJ, Picado-Leonard J, Chung B, et al. Assignment of the gene for adrenal P450c17 (steroid 17-alpha-hydroxylase / 17, 20 lyase) to human chromosome 10. *J Clin Endocrinol Metab* 1986;63:789-791
197. Yanase T, Simpson E and Waterman M. 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. *Endocr Rev* 1991;12:91-108
198. Rheaume E, Simard J, Morel Y, et al. Congenital adrenal hyperplasia due to point mutations in the type II 3-beta-hydroxysteroid dehydrogenase gene. *Nature* 1992;1:239-245
199. Trudel C, Couet J, Martel C, et al. Regulation of adrenal 3-beta-hydroxysteroid dehydrogenase expression and activity by adrenocorticotropin and corticosterone in the rat. *Endocrinology* 1991;129:2077-2084
200. Lorence MC, Corbin CJ, Kamimura N, et al. Structural analysis of the gene encoding human 3-beta-hydroxysteroid dehydrogenase. *Mol Endocrinol* 1990;4:1850-1855
201. Pang S. The molecular and clinical spectrum of 3 beta hydroxysteroid dehydrogenase deficiency disorder. *Trends in Endocrinology and Metabolism* 1998;9(2):82-86
202. Pang S. Congenital adrenal hyperplasia owing to 3 beta-hydroxysteroid dehydrogenase deficiency. *Endocrinol Metab Clin North Am* 2001;30:81-99
203. Pang S, Levine L, Stoner E, Opitz J, Pollack M, Dupont B and New M. Nonsalt-losing Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function. *J Clin Endocrinol Metab* 1983;56:808-818
204. Chang Y, Kulin H, Garibaldi L, Suriano M, Bracki K and Pang S. Hypothalamic-pituitary-gonadal axis function in pubertal male and female siblings with glucocorticoid-treated nonsalt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency Congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1993;77:1251-1257
205. Rosenfield R, Rich B, Wolfsdorf J, Cassorla F, Parks J, Bongiovanni A, Wu C and Shackleton C. Pubertal presentation of Congenital delta 5-3 beta-hydroxysteroid dehydrogenase deficiency. *J Clin Endocrinol Metab* 1980;51:345-353
206. Labrie F, Simard J, Luu-The V, Pelletier G, Belanger A, Lachance Y, Zhao H, Labrie C, Breton N, de LY, et al. Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. *J Steroid Biochem Mol Biol* 1992;41:421-435
207. Bogovich K, Payne AH. Purification of rat testicular microsomal 17-ketosteroid reductase. *J Biol Chem* 1980;255:5552-5559
208. Strnadova KA, Votava F, Lebl J, et al. Prevalence of Congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. *Eur J Pediatr* 2007;166:1-4
209. Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for Congenital adrenal hyperplasia ? *Horm Res* 2007;67:284-291
210. New MI. An update of Congenital adrenal hyperplasia. *Ann N Y Acad Sci* 2004;1038:14-43

211. Speiser P, White P. Congenital adrenal hyperplasia. *N Engl J Med* 2003;349:776-788
212. New M.I., Carlson A., Obeid J., Marshall I. et al. Prenatal diagnosis for Congenital adrenal hyperplasia in 595 pregnancies. *Endocrinologist* 2003;13:233-239
213. Nimkarn S, Weerakulwattana L, Chaichanwatanakul K, et al. Comprehensive study of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency in 92 Thai patients; in 11th Asian Congress of Pediatrics; 2003 November 2-7, Bangkok, Thailand, 11th Asian Congress of Pediatrics, 2003, p.80
214. Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. *Horm Res* 2002;58:188-195
215. Hughes I. Congenital adrenal hyperplasia: phenotype and genotype. *J Pediatr Endocrinol Metab* 2002;15(Suppl 5):1329-1340
216. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. *Pediatrics* 1995;95:120-125
217. Midgley PC, Russell K, Oates N, et al. Adrenal function in preterm infants: ACTH may not be the sole regulator of the fetal zone. *Pediatr Res* 1998;44:887-893
218. Ng PC. The fetal and neonatal hypothalamic-pituitary-adrenal axis. *Arch Dis Child Fetal Neonatal Ed* 2000;82:F25025-4
219. Ogilvy-Stuart A, Midgley P. Practical neonatal endocrinology. Cambridge University Press 2006;69-94
220. Southern, EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J Mol Biol* 1975;98:503-517
221. Puppo F, Indiveri F, Scudetti M, Ferrone S. Soluble HLA antigens: new roles and methods of application. *Immunol Today* 1997;18:154
222. Ze'ev Hochberg. Practical algorithms in pediatric endocrinology. Karger 2007;48-49
223. Ze'ev Hochberg. Practical algorithms in pediatric endocrinology. Karger 2007;50-51
224. WHO Multicentre growth reference study group. WHO Child growth standards based on length/height, weight and age. *Acta Paediatr*, 2006; Suppl 450: 76 – 85
225. Tanner J.M. Growth of the human at the time of adolescence. *Lect.Sci.Basis Med.* 1953,1:308– 63
226. Charmandari E, Hindmarsh P, Johnston A, Brook C. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. 2001, *J Clin Endocrinol Metab* 86: 2701 – 08
227. Merke DP, Bornstein SR, Avila NA, Chrousos GP. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 2002, *Ann Intern Med* 136: 320 – 34
228. Jaaskelainen J, Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. 2000, *Acta Paediatr* 89: 183 – 87
229. Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. 2009, *Best Pract Res Clin Endocrinol Metab* 23: 193 – 208
230. Forest MG. Adrenal Function Tests. In Ranke MB (ed): *Diagnostics of Endocrine Function in Children and Adolescents*. Basel, Karger, 2003, 372 – 426